Avidity Biosciences LLC
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2024 | $400 M | No. 3 | $250 million to $1 billion | equity, options | SEC | |
| Nov 2019 | $101 M | No. 2 | $50 to $250 million | equity | SEC | |
| Dec 2016 | $18 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Avidity Biosciences LLC chose not to state its revenue in its newest notice of a funding round (Mar 2024).
SEC Form D · Mar 2024
The industry group it chose in its notices: Biotechnology.
SEC Form D · Mar 2024
That is all the official record says: Avidity Biosciences LLC has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
6 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Alexandria Venture Investments, LLC | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Cormorant Asset Management, LP | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Cormorant Global Healthcare Master Fund, LP | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Cormorant Private Healthcare Fund II, LP | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Lilly Eli & Co | Other | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| RTW Investments, LP | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 45 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Arthur Levin | Executive officer | Mar 2024 |
| Michael Michael MacLean | Executive officer | Mar 2024 |
| Sarah Boyce | Executive officer | Mar 2024 |
| Teresa Michael McCarthy | Executive officer | Mar 2024 |
| W. Michael Flanagan | Executive officer | Mar 2024 |
| P. Kent Hawryluk | Executive officer | Jan 2017 |
| Troy Wilson PhD., JD | Executive officer | Jan 2017 |
| Carsten Michael Boess | Director | Mar 2024 |
| Edward Michael Kaye | Director | Mar 2024 |
| Jean Michael Kim | Director | Mar 2024 |
| Noreen Michael Henig | Director | Mar 2024 |
| Sarah Boyce | Director | Mar 2024 |
| Tamar Michael Thompson | Director | Mar 2024 |
| Troy Michael Wilson | Director | Mar 2024 |
| Edward Kaye | Director | Nov 2019 |
| Michael Martin | Director | Nov 2019 |
| Noreen Henig | Director | Nov 2019 |
| Roderick Wong | Director | Nov 2019 |
| Todd Brady | Director | Nov 2019 |
| Troy Wilson | Director | Nov 2019 |
| Michael Martin PhD. | Director | Jan 2017 |
| Troy Wilson PhD., JD | Director | Jan 2017 |